{"id":802247,"date":"2025-01-18T10:03:06","date_gmt":"2025-01-18T15:03:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/"},"modified":"2025-01-18T10:03:06","modified_gmt":"2025-01-18T15:03:06","slug":"bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/","title":{"rendered":"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Jan. 18, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <b><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4343362-1&amp;h=421886104&amp;u=https%3A%2F%2Fwww.rgrdlaw.com%2Fcases-bioage-labs-inc-class-action-lawsuit-bioa.html&amp;a=Robbins+Geller+Rudman+%26+Dowd+LLP\" target=\"_blank\" rel=\"nofollow\">Robbins <span class=\"xn-person\">Geller Rudman<\/span> &amp; Dowd LLP<\/a><\/b> announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and\/or traceable to BioAge Labs&#8217; registration statement issued in connection with BioAge Labs&#8217; initial public offering (the &#8220;IPO&#8221;) held on <span class=\"xn-chron\">September 26, 2024<\/span>, have until <span class=\"xn-chron\">March 10, 2025<\/span> to seek appointment as lead plaintiff of the <i>BioAge Labs <\/i>class action lawsuit. Captioned <i>Soto v. BioAge Labs, Inc.<\/i>, No. 25-cv-00196 (N.D. Cal.), the <i>BioAge Labs <\/i>class action lawsuit charges BioAge Labs\u00a0as well as certain of BioAge Labs&#8217; top executives and directors with violations of the Securities Act of 1933.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\" title=\"Robbins Geller Rudman &amp; Dowd LLP (PRNewsfoto\/Robbins Geller Rudman &amp; Dowd LLP)\" alt=\"Robbins Geller Rudman &amp; Dowd LLP (PRNewsfoto\/Robbins Geller Rudman &amp; Dowd LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>If you suffered substantial losses and wish to serve as lead plaintiff of the <i>BioAge Labs <\/i>class action lawsuit, please provide your information here:<\/b>\n      <\/p>\n<p>\n        <b><br \/>\n          <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4343362-1&amp;h=2533609467&amp;u=https%3A%2F%2Fwww.rgrdlaw.com%2Fcases-bioage-labs-inc-class-action-lawsuit-bioa.html&amp;a=https%3A%2F%2Fwww.rgrdlaw.com%2Fcases-bioage-labs-inc-class-action-lawsuit-bioa.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.rgrdlaw.com\/cases-bioage-labs-inc-class-action-lawsuit-bioa.html<\/a><br \/>\n        <\/b>\u00a0<\/p>\n<p>\n        <b>You can also contact attorneys <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4343362-1&amp;h=1685978872&amp;u=https%3A%2F%2Fwww.rgrdlaw.com%2Fcases-bioage-labs-inc-class-action-lawsuit-bioa.html&amp;a=J.C.+Sanchez\" target=\"_blank\" rel=\"nofollow\">J.C. Sanchez<\/a> or <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4343362-1&amp;h=1889480137&amp;u=https%3A%2F%2Fwww.rgrdlaw.com%2Fcases-bioage-labs-inc-class-action-lawsuit-bioa.html&amp;a=Jennifer+N.+Caringal\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Jennifer N. Caringal<\/span><\/a> of Robbins Geller by calling 800\/449-4900 or via e-mail at <a href=\"mailto:info@rgrdlaw.com\" target=\"_blank\" rel=\"nofollow\">info@rgrdlaw.com<\/a>.<\/b>\n      <\/p>\n<p>\n        <b>CASE ALLEGATIONS<\/b>: BioAge Labs is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. In the IPO, BioAge Labs sold 12.65 million shares at <span class=\"xn-money\">$18.00<\/span> per share.<\/p>\n<p>The <i>BioAge Labs <\/i>class action lawsuit <span>alleges<\/span> that the IPO&#8217;s offering documents were materially false and\/or misleading because they represented to the public that there were no safety concerns and BioAge Labs expected top line results and to meet its primary endpoint goals in connection with its STRIDES clinical trial.<\/p>\n<p>The <i>BioAge Labs <\/i>class action lawsuit further <span>alleges<\/span> that on <span class=\"xn-chron\">December 6, 2024<\/span>, BioAge Labs announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag. On this news, the price of BioAge Labs stock fell more than 76%, according to the complaint. By the commencement of the <i>BioAge Labs<\/i> class action lawsuit, BioAge Labs stock has traded at or around <span class=\"xn-money\">$5.82<\/span> per share, which is well below the <span class=\"xn-money\">$18.00<\/span> per share IPO price.<\/p>\n<p>\n        <b>THE LEAD PLAINTIFF PROCESS<\/b>: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired BioAge Labs stock pursuant and\/or traceable to the registration statement issued in connection with the IPO to seek appointment as lead plaintiff in the <i>BioAge Labs <\/i>class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the <i>BioAge Labs <\/i>class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the <i>BioAge Labs<\/i> class action lawsuit. An investor&#8217;s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the <i>BioAge Labs <\/i>class action lawsuit.<\/p>\n<p>\n        <b>ABOUT ROBBINS GELLER<\/b>: Robbins Geller Rudman &amp; Dowd LLP is one of the world&#8217;s leading law firms representing investors in securities <span>fraud<\/span> cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered <span class=\"xn-money\">$6.6 billion<\/span> for investors in securities-related class action cases \u2013 over <span class=\"xn-money\">$2.2 billion<\/span> more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs&#8217; firms in the world and the Firm&#8217;s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever \u2013 <span class=\"xn-money\">$7.2 billion<\/span> \u2013 in <i>In re Enron Corp. Sec. Litig.<\/i> Please visit the following page for more information:<\/p>\n<p>\n        <b><br \/>\n          <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4343362-1&amp;h=312063059&amp;u=https%3A%2F%2Fwww.rgrdlaw.com%2Fservices-litigation-securities-fraud.html&amp;a=https%3A%2F%2Fwww.rgrdlaw.com%2Fservices-litigation-securities-fraud.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.rgrdlaw.com\/services-litigation-securities-<span>fraud<\/span>.html<\/a><br \/>\n        <\/b>\n      <\/p>\n<p>Past results do not guarantee future outcomes.<br \/>Services may be performed by attorneys in any of our offices.\u00a0<\/p>\n<p>Contact:<\/p>\n<p class=\"prnml40\">Robbins\u00a0Geller Rudman &amp; Dowd LLP<br \/>J.C. Sanchez, <span class=\"xn-person\">Jennifer N. Caringal<\/span><br \/>655 W. Broadway, Suite 1900, <span class=\"xn-location\">San Diego, CA<\/span> 92101<br \/>800-449-4900<br \/><b><a href=\"mailto:info@rgrdlaw.com\" target=\"_blank\" rel=\"nofollow\">info@rgrdlaw.com<\/a><\/b>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA99226&amp;sd=2025-01-18\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit-302354481.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit-302354481.html<\/a><\/p>\n<p>SOURCE  Robbins Geller Rudman &amp; Dowd LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA99226&amp;Transmission_Id=202501181000PR_NEWS_USPR_____LA99226&amp;DateId=20250118\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO , Jan. 18, 2025 \/PRNewswire\/ &#8212; Robbins Geller Rudman &amp; Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and\/or traceable to BioAge Labs&#8217; registration statement issued in connection with BioAge Labs&#8217; initial public offering (the &#8220;IPO&#8221;) held on September 26, 2024, have until March 10, 2025 to seek appointment as lead plaintiff of the BioAge Labs class action lawsuit. Captioned Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), the BioAge Labs class action lawsuit charges BioAge Labs\u00a0as well as certain of BioAge Labs&#8217; top executives and directors with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-802247","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , Jan. 18, 2025 \/PRNewswire\/ &#8212; Robbins Geller Rudman &amp; Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and\/or traceable to BioAge Labs&#8217; registration statement issued in connection with BioAge Labs&#8217; initial public offering (the &#8220;IPO&#8221;) held on September 26, 2024, have until March 10, 2025 to seek appointment as lead plaintiff of the BioAge Labs class action lawsuit. Captioned Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), the BioAge Labs class action lawsuit charges BioAge Labs\u00a0as well as certain of BioAge Labs&#8217; top executives and directors with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of &hellip; Continue reading &quot;BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-18T15:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit\",\"datePublished\":\"2025-01-18T15:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/\"},\"wordCount\":676,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/\",\"name\":\"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"datePublished\":\"2025-01-18T15:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , Jan. 18, 2025 \/PRNewswire\/ &#8212; Robbins Geller Rudman &amp; Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and\/or traceable to BioAge Labs&#8217; registration statement issued in connection with BioAge Labs&#8217; initial public offering (the &#8220;IPO&#8221;) held on September 26, 2024, have until March 10, 2025 to seek appointment as lead plaintiff of the BioAge Labs class action lawsuit. Captioned Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), the BioAge Labs class action lawsuit charges BioAge Labs\u00a0as well as certain of BioAge Labs&#8217; top executives and directors with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of &hellip; Continue reading \"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-18T15:03:06+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit","datePublished":"2025-01-18T15:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/"},"wordCount":676,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/","name":"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","datePublished":"2025-01-18T15:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioa-investor-alert-bioage-labs-inc-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BIOA INVESTOR ALERT: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=802247"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802247\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=802247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=802247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=802247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}